GSTM1 and anemia: Because the patients receiving S/V therapy with decreasing Hb exhibited higher mortality rates and lower survival rates than did those with stable Hb, we grouped patients by whether they had received such anemia treatment into erythropoietin, folate, vitamin B12, and iron groups.